Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
INmune Bio Inc. - Common stock
(NQ:
INMB
)
1.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 27, 2025
Via
Benzinga
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
↗
January 23, 2025
Via
Benzinga
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
December 10, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
December 04, 2024
From
OmniScience
Via
Business Wire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
December 04, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
November 13, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
October 28, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
October 24, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
October 24, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
October 11, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
September 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
September 26, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
September 17, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces $13.0 Million Registered Direct Offering
September 13, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
September 03, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
July 29, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
July 25, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
July 23, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
June 27, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
INmune Bio Inc. to Join Russell 3000® Index
May 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
May 07, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
April 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
April 29, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 25, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
April 23, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
April 22, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
April 08, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
↗
March 28, 2024
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
